CannTrust Sends Shipment of CBD Oil to Australia for Research

CannTrust Holdings (TSX:TRST) announced the shipment of standardized cannabidiol (CBD) oil capsules to Australia’s Gold Coast University Hospital for research and study purposes.

As quoted in the press release:

The capsules will be used in a study to determine the efficacy of CannTrust CBD oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND), which was first announced by the Company in July 2018. The capsules will be imported, stored and distributed by PharmaCann Pty Ltd (“PharmaCann”). The shipment will include all investigational products that are required for the study.

“With our medicinal cannabis experience and over 50,000 patients enrolled over the past five years, we continue to see the medical potential of the cannabis plant. We are committed to being international leaders in the generation of scientific evidence proving the medical benefits in treating a variety of indications. With hundreds of thousands of people living with ALS in Canada and globally, we continue to focus on improving peoples’ lives around the world,” says Peter Aceto, CEO of CannTrust. “We also thank PharmaCann for its expertise and assistance in importing our products to Australia, to make this study possible.”

Click here to read the full press release.

Source: www.newswire.ca